The effects of a second RNA therapeutic, inotersen36, and a second transthyretin tetramer stabilizer, AG1037, on cardiac structure and function in adults with transthyretin amyloid cardiomyopathy are unclear. This evidence concerns the gene TTR and prealbumin measurement.